Reaction

Seborrhoeic Dermatitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,621 reports · 42 co-occurring drugs

As of the last recalculation, Seborrhoeic Dermatitis appears in 1,621 FAERS reports alongside 42 co-occurring drug terms. The strongest observed disproportionality signal is KETOCONAZOLE (PRR 78.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ketoconazole	99	78.1	78.6
Ketoconazole Cream, 2%	83	75.6	76.0
Ketoconazole Foam	82	75.0	75.4
Terbinafine Hydrochloride	17	24.8	24.9
Clobetasol Propionate Ointment Usp, 0.05%	14	17.6	17.6
Clobetasol Propionate	13	16.3	16.3
Methylprednisolone Acetate	10	16.1	16.1
Atazanavir	15	13.5	13.5
Triamcinolone Acetonide Ointment Usp, 0.05%	23	12.8	12.8
Finasteride	54	11.9	11.9
Mupirocin	12	11.5	11.5
Mupirocin Calcium	12	11.3	11.3
Fexofenadine Hcl	8	11.2	11.2
Ritonavir	23	10.2	10.2
Gefitinib	7	10.0	10.0
Triamcinolone Acetonide	23	9.7	9.7
Zidovudine	10	9.7	9.7
Brexpiprazole	12	9.3	9.3
Erlotinib Hydrochloride	8	8.2	8.2
Erlotinib	6	8.0	8.0
Minoxidil	27	7.8	7.8
Raltegravir	10	7.8	7.8
Mesna Injection	5	7.8	7.8
Mesna	5	7.6	7.7
Panitumumab	9	7.4	7.4
Nevirapine	5	7.1	7.1
Minoxidil Foam 5% (Womens)	18	7.1	7.1
Bimekizumab	11	6.7	6.7
Entecavir	6	6.6	6.6
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	9	6.4	6.4
Isotretinoin	24	6.3	6.3
Secukinumab	75	6.2	6.2
Miconazole Nitrate	4	5.9	5.9
Vemurafenib	5	5.4	5.4
Pseudoephedrine Hydrochloride	4	5.0	5.0
Pseudoephedrine Hcl	4	4.7	4.7
Emtricitabine And Tenofovir Alafenamide	4	4.5	4.5
Dupilumab	146	4.2	4.2
Cetuximab	10	4.1	4.1
Ixekizumab	11	3.8	3.8
Guselkumab	8	2.9	2.9
Adapalene	6	0.4	0.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.